Tirzepatide (Mounjaro) 30mg

Tirzepatide (Mounjaro) 30mg

Tirzepatide 30mg refers to a high-strength formulation concept of a dual incretin receptor agonist used in metabolic research and clinical contexts related to blood glucose and appetite regulation. The active compound is marketed in prescription form under Mounjaro.

⚠️ Note: A 30mg strength is not a standard commercially approved dosing presentation in most regulated medical products and may refer to research, compounded, or bulk peptide formulations depending on source and jurisdiction.

🔬 Key Benefits (Clinical & Research Context)

• Studied for glycemic control in type 2 diabetes models
• Investigated for appetite and energy intake regulation
• Supports research into insulin sensitivity and metabolic pathways
• Explored in dose-response metabolic studies

⚙️ Mechanism of Action

Tirzepatide acts as a dual incretin agonist, targeting:

• GIP (glucose-dependent insulinotropic polypeptide) receptors
• GLP-1 (glucagon-like peptide-1) receptors

This leads to:

• Enhanced insulin secretion (glucose-dependent)
• Reduced glucagon release
• Slower gastric emptying
• Increased satiety and reduced appetite

🧬 Product Details

• Active ingredient: Tirzepatide
• Strength: 30 mg (non-standard / research-referenced strength)
• Class: Dual GIP/GLP-1 receptor agonist
• Form: Injectable formulation (varies by supplier context)
• Primary use: Metabolic and endocrine research